Price and Review,an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine

Acetylcholinesterase (AChE), a pivotal enzyme within the nervous system, is primarily recognized for its critical role in neurotransmission. Its canonical function involves the rapid hydrolysis of the neurotransmitter acetylcholine (ACh) into acetate and choline. This enzymatic breakdown, occurring at the synaptic cleft, is essential for terminating nerve signals and allowing for the subsequent repolarization of the neuron. The enzyme itself is a member of the α/β-hydrolase fold superfamily of proteins and acts as a serine hydrolase, a classification highlighting its catalytic mechanism involving a key serine residue within its active site, often part of a Glu327–His440–Ser200 catalytic triad. This triad is crucial for the hydrolysis of ester bonds.

While the hydrolysis of acetylcholine is its most well-documented function, emerging research reveals a more multifaceted profile for acetylcholinesterase. Beyond its primary role, acetylcholinesterase exhibits a spectrum of non-hydrolytic functions, suggesting a broader impact on cellular processes. For instance, peptides cleaved from AChE can function as independent signaling molecules, hinting at complex regulatory pathways. Furthermore, acetylcholinesterase has been shown to interact with various peptides, including amyloid-beta (Aβ) peptide.

Interestingly, while acetylcholinesterase is responsible for the hydrolysis of acetylcholine, its interaction with amyloid precursor protein peptides is more nuanced. Studies have indicated that Brain Acetylcholinesterase Promotes Amyloid-β-Peptide Aggregation but, importantly, does not hydrolyze amyloid precursor protein peptides. This distinction is significant, as it suggests that AChE's role in neurodegenerative conditions like Alzheimer's disease may involve promoting the aggregation of amyloid plaques rather than directly breaking them down. The enzyme's association with amyloid-beta peptide can lead to the formation of stable complexes, and its structural motifs can promote fibril formation.

The preparation of acetylcholinesterase inhibitory peptides from various sources, such as yellowfin tuna pancreas or pea protein hydrolysates, is an active area of research. These peptides, obtained through enzymatic digestion or moderate ultrasound-assisted enzymatic hydrolysis, demonstrate potential as therapeutic agents for conditions like Alzheimer's disease, where inhibiting AChE activity is a common treatment strategy. The study of acetylcholinesterase and butyrylcholinesterase inhibitory peptides from sources like pea protein hydrolysates highlights the diverse biological activities that can arise from protein fragmentation.

The enzymatic process of acetylcholine hydrolysis by acetylcholinesterase involves the substrate binding to the enzyme's active site. Here, the ester bond of acetylcholine is cleaved. This process can be studied using chromogenic substrates like acetylthiocholine, which generates a product (TCh) enzymatically by hydrolysis, displaying kinetic properties virtually identical to those of acetylcholine hydrolysis. The mechanism of hydrolysis is accomplished by the aforementioned catalytic triad and an oxyanion hole.

In summary, acetylcholinesterase is far more than just an enzyme that breaks down acetylcholine. Its involvement in peptide interactions, its role in promoting amyloid aggregation, and the potential therapeutic applications of acetylcholinesterase inhibitory peptides underscore its complex and diverse biological significance. Understanding the intricacies of acetylcholinesterase and its interactions, including those involving peptide hydrolysis and non-hydrolytic functions, is crucial for advancing our knowledge of neurological processes and developing novel therapeutic strategies.